US drug maker Gilead Pharma says
that the recent decision by the patent office, which rejected patent for one of
its molecules, does not impact its India plans.
Gilead has announced that it is
expanding the voluntary licence agreement with eight Indian companies to
include its experimental drug that could cure all the six types of hepatitis C.
The American biotechnology company
also makes the new hepatitis C drug Sofosbuvir. Last year, Gilead signed a
licensing agreement with Strides, Mylan, Cipla, Dr Reddys, Ranbaxy, Zydus
Cadila for Sovaldi.
The drug, priced at $84,000 in US
for 12-week treatment, will be sold at $900 in India. It is expected to launch
the drug in coming months in India, says the company.
Gregg Alton executive vice-president to ET said that, "We believe that
Gilead and Indian companies can make a difference to the world through such
Alton also said that the decision by the patent office is only for one of the
ancillary molecules and the company does not see this decision as an indication
of India's policy on intellectual property.